Barclays raised the firm’s price target on Karyopharm (KPTI) to $10 from $5 and keeps an Overweight rating on the shares. The company’s Q1 selinexor revenue of $21.1M was below consensus of $28.7M, but the key focus for investors is on pivotal myelofibrosis data in late 2025/early 2026, the analyst tells investors in a research note. The firm adjusted its model to account for the recent stock split.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
- Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
- Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
- KPTI Earnings this Week: How Will it Perform?
- Biotech stocks slide as Marks resignation seen being negative for sector
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue